261 related articles for article (PubMed ID: 8286195)
1. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
Leek RD; Kaklamanis L; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 1994 Jan; 69(1):135-9. PubMed ID: 8286195
[TBL] [Abstract][Full Text] [Related]
2. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
van Slooten HJ; Clahsen PC; van Dierendonck JH; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van de Velde CJ; van de Vijver MJ
Br J Cancer; 1996 Jul; 74(1):78-85. PubMed ID: 8679463
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
[TBL] [Abstract][Full Text] [Related]
5. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.
Horak E; Smith K; Bromley L; LeJeune S; Greenall M; Lane D; Harris AL
Oncogene; 1991 Dec; 6(12):2277-84. PubMed ID: 1685017
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
[TBL] [Abstract][Full Text] [Related]
10. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
[TBL] [Abstract][Full Text] [Related]
12. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.
Gorczyca W; Markiewski M; Kram A; Tuziak T; Domagala W
Virchows Arch; 1995; 426(3):229-33. PubMed ID: 7773501
[TBL] [Abstract][Full Text] [Related]
14. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
15. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour.
Ceccarelli C; Santini D; Chieco P; Taffurelli M; Marrano D; Mancini AM
Ann Oncol; 1995 Mar; 6(3):275-82. PubMed ID: 7612493
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma.
Sierra A; Lloveras B; Castellsagué X; Moreno L; García-Ramirez M; Fabra A
Int J Cancer; 1995 Jan; 60(1):54-60. PubMed ID: 7814152
[TBL] [Abstract][Full Text] [Related]
17. [Expression of oestrogen receptor-beta in invasive breast tumours].
Péter I; Számel I; Péley G
Magy Onkol; 2004; 48(1):63-9. PubMed ID: 15105898
[TBL] [Abstract][Full Text] [Related]
18. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group.
Nathan B; Gusterson B; Jadayel D; O'Hare M; Anbazhagan R; Jayatilake H; Ebbs S; Micklem K; Price K; Gelber R
Ann Oncol; 1994 May; 5(5):409-14. PubMed ID: 7915536
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
